Current Insights for the Management of Acne in the Modern Era

Author(s): Neha Singh, Apoorva Singh, Kalpana Pandey, Nimisha*

Journal Name: Recent Patents on Anti-Infective Drug Discovery
Continued as Recent Advances in Anti-Infective Drug Discovery

Volume 15 , Issue 1 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Acne vulgaris a chronic disease which is caused by blockage of the sebaceous gland is commonly seen in almost every human being at some point in their lives. There are 20-25% chances of progression of acne to severe cases, which leads to permanent scarring that results in psychological problems like depression, social isolation, lowered self-esteem, and lowered self-confidence.

Objective: Though several conventional treatments are available in the market but still there are various adverse effects associated with topical anti-acne agents due to which it lacks patient compatibility. The present study is undertaken to find out the major shortcoming; why the current therapies do not give the desired therapeutic results.

Conclusion: Novel drug delivery strategies can play a crucial role in the enhancement of topical delivery of anti-acne agents by escalating their dermal localization and reducing their adverse effects. Consumption of medicinal plants like Aloe vera, Withania somniferia etc. have clinical evidence regarding the effective management of acne. The current inclination towards nanotechnology is considerable due to several changes in the pharmaceutical research area. To secure the research work in different pharmaceutical fields, patents are filed against various agents like Galderma Research & Development have filed patents for adapalene and benzoyl peroxide for the management of acne vulgaris. The current review highlights the potential of various novel drug delivery approaches like liposomes, niosomes, ethosomes, transfersomes etc. in enhancing the topical delivery of anti-acne agents.

Keywords: Acne, conventional, dermal, liposome, niosome, sebaceous gland.

[1]
Vyas A, Kumar Sonker A, Gidwani B. Carrier-based drug delivery system for treatment of acne. Sci World J 2014; 2014
[http://dx.doi.org/10.1155/2014/276260]
[2]
Sittart JA. Costa Ad, Mulinari-Brenner F, Follador I, Azulay-Abulafia L, Castro LC. Multicenter study for efficacy and safety evaluation of a fixeddose combination gel with adapalen 0.1% and benzoyl peroxide 2.5% (Epiduo® for the treatment of acne vulgaris in Brazilian population. An Bras Dermatol 2015; 90(6)(Suppl. 1): 1-16.
[http://dx.doi.org/10.1590/abd1806-4841.20153969] [PMID: 27168522]
[3]
Burton JL, Cunliffe WJ, Stafford I, Shuster S. The prevalence of acne vulgaris in adolescence. Br J Dermatol 1971; 85(2): 119-26.
[http://dx.doi.org/10.1111/j.1365-2133.1971.tb07195.x] [PMID: 4255129]
[4]
Plewig G, Melnik B, Chen W. Acne Epidemiology and genetics InPlewig and Kligman’s acne and rosacea. Cham: Springer 2019; pp. 35-44.
[5]
Götz H, Zabel G. Acne vulgaris in 2,249 high-school students in the 12-20 years age group G Ital Dermatol Minerva Dermatol 1971; 46(3): 133-6.
[PMID: 4254698]
[6]
Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologists. BMJ 1989; 298(6682): 1217-9.
[http://dx.doi.org/10.1136/bmj.298.6682.1217] [PMID: 2526674]
[7]
Schäfer T, Nienhaus A, Vieluf D, Berger J, Ring J. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001; 145(1): 100-4.
[http://dx.doi.org/10.1046/j.1365-2133.2001.04290.x] [PMID: 11453915]
[8]
Rzany B, Kahl C. Epidemiology of acne vulgaris J Dtsch Dermatol Ges 2006; 4(1): 8-9.
[http://dx.doi.org/10.1111/j.1610-0387.2005.05876.x] [PMID: 16503926]
[9]
Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. BMJ 1979; 1(6171): 1109-10.
[http://dx.doi.org/10.1136/bmj.1.6171.1109] [PMID: 156054]
[10]
Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001; 15(6): 541-5.
[http://dx.doi.org/10.1046/j.1468-3083.2001.00357.x] [PMID: 11843213]
[11]
Fyrand O, Fiskaadal HJ, Trygstad O. Acne in pubertal boys undergoing treatment with androgens. Acta Derm Venereol 1992; 72(2): 148-9.
[PMID: 1350406]
[12]
Jemec GB, Linneberg A, Nielsen NH, Frølund L, Madsen F, Jørgensen T. Have oral contraceptives reduced the prevalence of acne? a population-based study of acne vulgaris, tobacco smoking and oral contraceptives. Dermatology (Basel) 2002; 204(3): 179-84.
[http://dx.doi.org/10.1159/000057878] [PMID: 12037444]
[13]
Chuh AA, Zawar V, Wong WC, Lee A. Clinical and experimental dermatology. The association of smoking and acne in men in Hong Kong and in India: a retrospective case-control study in primary care settings. Clin Exp Dermatol 2004; 29(6): 597-9.
[http://dx.doi.org/10.1111/j.1365-2230.2004.01646.x] [PMID: 15550130]
[14]
Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne--a twin study. Br J Dermatol 1988; 118(3): 393-6.
[http://dx.doi.org/10.1111/j.1365-2133.1988.tb02433.x] [PMID: 2965597]
[15]
Bataille V, Snieder H, MacGregor AJ, Sasieni P, Spector TD. The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol 2002; 119(6): 1317-22.
[http://dx.doi.org/10.1046/j.1523-1747.2002.19621.x] [PMID: 12485434]
[16]
Manfredini M, Greco M, Farnetani F, Ciardo S, De Carvalho N, Mandel VD, et al. Acne: morphologic and vascular study of lesions and surrounding skin by means of optical coherence tomography. J Eur Acad Dermatol Venereol 2017; 31(9): 1541-6.
[http://dx.doi.org/10.1111/jdv.14369] [PMID: 28556980]
[17]
Liao DC. Management of acne. J Fam Pract 2003; 52(1): 43-51.
[PMID: 12540312]
[18]
Trivedi MK, Bosanac SS, Sivamani RK, Larsen LN. Emerging therapies for acne vulgaris. Am J Clin Dermatol 2018; 19(4): 505-16.
[http://dx.doi.org/10.1007/s40257-018-0345-x] [PMID: 29594974]
[19]
Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol 2005; 4(1): 41-7.
[PMID: 15696984]
[20]
Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol 1998; 39(2 Pt 3): S38-44.
[http://dx.doi.org/10.1016/S0190-9622(98)70443-8] [PMID: 9703122]
[21]
Domínguez J, Hojyo MT, Celayo JL, Domínguez-Soto L, Teixeira F. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998; 37(1): 54-5.
[http://dx.doi.org/10.1046/j.1365-4362.1998.00254.x] [PMID: 9522243]
[22]
Elbaum DJ. Comparison of the stability of topical isotretinoin and topical tretinoin and their efficacy in acne. J Am Acad Dermatol 1988; 19(3): 486-91.
[http://dx.doi.org/10.1016/S0190-9622(88)70202-9] [PMID: 2971693]
[23]
Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology (Basel) 1999; 199(3): 242-7.
[http://dx.doi.org/10.1159/000018255] [PMID: 10592405]
[24]
Kosmadaki M, Katsambas A. Topical treatments for acne. Clin Dermatol 2017; 35(2): 173-8.
[http://dx.doi.org/10.1016/j.clindermatol.2016.10.010] [PMID: 28274355]
[25]
Bardazzi F, Savoia F, Parente G, Tabanelli M, Balestri R, Spadola G, et al. Azithromycin: a new therapeutical strategy for acne in adolescents. Dermatol Online J 2007; 13(4): 4.
[PMID: 18319001]
[26]
Dréno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H. European Expert Group on Oral Antibiotics in Acne. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004; 14(6): 391-9.
[PMID: 15564203]
[27]
Cotterill JA, Cunliffe WJ, Forster RA, Williamson DM, Bulusu L. A comparison of trimethoprim-sulphamethoxazole with oxytetracycline in acne vulgaris. Br J Dermatol 1971; 84(4): 366-9.
[http://dx.doi.org/10.1111/j.1365-2133.1971.tb14233.x] [PMID: 4252527]
[28]
Leyden JJ, Del Rosso JQ. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol 2011; 4(2): 40-7.
[PMID: 21386956]
[29]
Leydon J. Comparing facial tolerability of a 3-step acne system containing a novel solubilized 5% benzoyl peroxide lotion for normal to dry skin with that of a benzoyl peroxide/clindamycin combination prescription product. J Am Acad Dermatol 2008; 58(2)(Suppl. 2): 15.
[30]
Nimisha FZ, Kaur CD, Rizvi DA. Berberine chloride dihydrate enthused nanovesicles for the management of dermatitis nanovesicles for dermatitis. Nanosci Nanotechnol Asia 2020; 10: 1.
[http://dx.doi.org/10.2174/2210681210666200313123550]
[31]
Wang F, Kwak HS, Elbuluk N, Kaczmarek AL, Hamilton T, Voorhees JJ, et al. Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne. J Am Acad Dermatol 2009; 61(2): 252-8.
[http://dx.doi.org/10.1016/j.jaad.2009.03.013] [PMID: 19525031]
[32]
Gabriëls M, Brisaert M, Plaizier-Vercammen J. Densitometric thin layer chromatographic analysis of tretinoin and erythromycin in lotions for topical use in acne treatment. Eur J Pharm Biopharm 1999; 48(1): 53-8.
[http://dx.doi.org/10.1016/S0939-6411(99)00021-1] [PMID: 10477329]
[33]
Spellman MC, Pincus SH. Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne. Clin Ther 1998; 20(4): 711-21.
[http://dx.doi.org/10.1016/S0149-2918(98)80134-3] [PMID: 9737831]
[34]
Verschoore M, Poncet M, Czernielewski J, Sorba V, Clucas A. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol 1997; 36(6 Pt 2): S104-9.
[http://dx.doi.org/10.1016/S0190-9622(97)70051-3] [PMID: 9204086]
[35]
Shalita AR, Berson DS, Thiboutot DM, Leyden JJ, Parizadeh D, Sefton J, et al. Tazarotene cream in acne clinical study investigator group. effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther 2004; 26(11): 1865-73.
[http://dx.doi.org/10.1016/j.clinthera.2004.11.012] [PMID: 15639698]
[36]
Xu YL, Yang XX, Xu S. Preparation and evaluation of tea tree oil liposome. Huaxi Yaoxue Zazhi 2006; 21(2): 139.
[37]
Rougier AM, Richard A. Efficacy and safety of a new salicylic acid derivative as a complement of vitamin A acid in acne treatment. J Am Acad Dermatol 2004; 50(3): 19.
[http://dx.doi.org/10.1016/j.jaad.2003.10.078]
[38]
Yaroshinsky A, Leyden J. The safety and efficacy of clindamycin (1% as clindamycin phosphate and tretinoin (0.025%)] for the treatment of acne vulgaris: a combined analysis of results from six controlled safety and efficacy trials conducted in Europe 1. J Am Acad Dermatol 2004; 50(3): 23.
[http://dx.doi.org/10.1016/j.jaad.2003.10.094]
[39]
Vermeulen B, Remon JP, Nelis H. The formulation and stability of erythromycin-benzoyl peroxide in a topical gel. Int J Pharm 1999; 178(1): 137-41.
[http://dx.doi.org/10.1016/S0378-5173(98)00366-4] [PMID: 10205634]
[40]
Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone Gel Long-Term Safety Study Group. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007; 6(10): 981-7.
[PMID: 17966175]
[41]
Del Rosso JQ. The use of sodium sulfacetamide 10%-sulfur 5% emollient foam in the treatment of acne vulgaris. J Clin Aesthet Dermatol 2009; 2(8): 26-9.
[PMID: 20729951]
[42]
Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol 2006; 19(1): 2-16.
[http://dx.doi.org/10.1159/000089138] [PMID: 16247244]
[43]
Gulati M, Grover M, Singh S, Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm 1998; 165(2): 129-68.
[http://dx.doi.org/10.1016/S0378-5173(98)00006-4]
[44]
Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003; 8(24): 1112-20.
[http://dx.doi.org/10.1016/S1359-6446(03)02903-9] [PMID: 14678737]
[45]
Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998; 53(1-3): 275-9.
[http://dx.doi.org/10.1016/S0168-3659(97)00261-7] [PMID: 9741935]
[46]
Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997; 54(4)(Suppl. 4): 8-14.
[http://dx.doi.org/10.2165/00003495-199700544-00004] [PMID: 9361956]
[47]
Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 2007; 1768(5): 1121-7.
[http://dx.doi.org/10.1016/j.bbamem.2007.01.019] [PMID: 17321495]
[48]
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013; 8(1): 102.
[http://dx.doi.org/10.1186/1556-276X-8-102] [PMID: 23432972]
[49]
Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005; 16(7): 691-707.
[http://dx.doi.org/10.1097/01.cad.0000167902.53039.5a] [PMID: 16027517]
[50]
Mezei M, Gulasekharam V. Liposomes--a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980; 26(18): 1473-7.
[http://dx.doi.org/10.1016/0024-3205(80)90268-4] [PMID: 6893068]
[51]
Lieb LM, Ramachandran C, Egbaria K, Weiner N. Topical delivery enhancement with multilamellar liposomes into pilosebaceous units: I. In vitro evaluation using fluorescent techniques with the hamster ear model. J Invest Dermatol 1992; 99(1): 108-13.
[http://dx.doi.org/10.1111/1523-1747.ep12611886] [PMID: 1607674]
[52]
Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother 2010; 21(2): 53-70.
[http://dx.doi.org/10.3851/IMP1684] [PMID: 21107015]
[53]
Škalko N, Čajkovac M, Jalšenjak I. Liposomes with clindamycin hydrochloride in the therapy of acne vulgaris. Int J Pharm 1992; 85(1-3): 97-101.
[http://dx.doi.org/10.1016/0378-5173(92)90138-R]
[54]
Honzak L, Šentjurc M. Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pflugers Arch 2000; 440(1)(Suppl. 1): R044-5.
[http://dx.doi.org/10.1007/s004240000000] [PMID: 28008476]
[55]
Sankar C, Muthukumar S, Arulkumaran G, Shalini S, Sundaraganapathy R. Formulation and Characterization of Liposomes containing Clindamycin and Green tea for Anti Acne. Research Journal of Pharmacy and Technology 2019; 12(12): 5977-84.
[http://dx.doi.org/10.5958/0974-360X.2019.01038.2]
[56]
Madan S, Nehate C, Barman TK, Rathore AS, Koul V. Design, preparation, and evaluation of liposomal gel formulations for treatment of acne: in vitro and in vivo studies. Drug Dev Ind Pharm 2019; 45(3): 395-404.
[http://dx.doi.org/10.1080/03639045.2018.1546310] [PMID: 30442066]
[57]
Aytekin AA, Tuncay Tanrıverdi S, Aydın Köse F, Kart D, Eroğlu İ, Özer Ö. Propolis loaded liposomes: evaluation of antimicrobial and antioxidant activities. J Liposome Res 2019; 30(2): 1-0.
[PMID: 30913939]
[58]
Malhotra M, Jain NK. Niosomes as drug carriers. Indian Drugs-Bombay 1994; 31: 81.
[59]
Udupa N. Niosomes as drug carriers Controlled and novel drug delivery. 1st ed. New Delhi: CBS Publishers and Distributors 2002.
[60]
Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes--non-ionic surfactant vesicles. J Pharm Pharmacol 1985; 37(12): 863-8.
[http://dx.doi.org/10.1111/j.2042-7158.1985.tb04990.x] [PMID: 2868092]
[61]
Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm 1999; 185(1): 23-35.
[http://dx.doi.org/10.1016/S0378-5173(99)00122-2] [PMID: 10425362]
[62]
Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology 1992; 75(4): 570-5.
[PMID: 1592432]
[63]
Moser P, Marchand-Arvier M, Labrude P, Handjani-Vila RM, Vigneron C. Hemoglobin niosomes. I. Preparation, functional and physico-chemical properties, and stability Pharm Acta Helv 1989; 64(7): 192-202.
[PMID: 2762361]
[64]
Moser P, Marchand-Arvier M, Labrude P, Vigneron C. Hemoglobin niosomes. II. In vitro interactions of plasma proteins and phagocytes Pharm Acta Helv 1990; 65(3): 82-92.
[PMID: 2185479]
[65]
Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol 1988; 40(3): 161-5.
[http://dx.doi.org/10.1111/j.2042-7158.1988.tb05210.x] [PMID: 2899143]
[66]
Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res 2010; 1(4): 374-80.
[http://dx.doi.org/10.4103/0110-5558.76435] [PMID: 22247876]
[67]
Hofland HE, van der Geest R, Bodde HE, Junginger HE, Bouwstra JA. Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in vitro. Pharm Res 1994; 11(5): 659-64.
[http://dx.doi.org/10.1023/A:1018963910260] [PMID: 8058633]
[68]
Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm 2002; 234(1-2): 237-48.
[http://dx.doi.org/10.1016/S0378-5173(01)00971-1] [PMID: 11839454]
[69]
Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B 2011; 1(4): 208-19.
[http://dx.doi.org/10.1016/j.apsb.2011.09.002]
[70]
Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in-vitro characterization, skin irritation test and comparative clinical study. Drug Deliv 2015; 22(6): 731-9.
[http://dx.doi.org/10.3109/10717544.2014.896428] [PMID: 24670094]
[71]
Budhiraja A, Dhingra G. Development and characterization of a novel antiacne niosomal gel of rosmarinic acid. Drug Deliv 2015; 22(6): 723-30.
[http://dx.doi.org/10.3109/10717544.2014.903010] [PMID: 24786487]
[72]
Gupta A, Singh S, Kotla NG, Webster TJ. Formulation and evaluation of a topical niosomal gel containing a combination of benzoyl peroxide and tretinoin for antiacne activity. Int J Nanomedicine 2014; 10: 171-82.
[PMID: 25565812]
[73]
Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv 2015; 22(8): 1027-42.
[http://dx.doi.org/10.3109/10717544.2013.855277] [PMID: 24251352]
[74]
Jigar V, Puja V, Krutika S. Formulation and evaluation of topical niosomal gel of erythromycin. Int J Pharm Pharm Sci 2011; 3(1): 123-6.
[75]
Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65(3): 403-18.
[http://dx.doi.org/10.1016/S0168-3659(99)00222-9] [PMID: 10699298]
[76]
Pandey K. Nimisha. An overview on promising nanotechnological approaches for the treatment of psoriasis. Recent Pat Nanotechnol 2020; 14: 1.
[http://dx.doi.org/10.2174/1872210514666200204124130] [PMID: 32013854]
[77]
Nimisha, Rizvi DA, Fatima Z, Neema, Kaur CD. Antipsoriatic and anti-inflammatory studies of Berberis aristata extract loaded nanovesicular gels. Pharmacogn Mag 2017; 13(Suppl. 3): S587-94.
[http://dx.doi.org/10.4103/pm.pm_210_17] [PMID: 29142419]
[78]
Anitha P, Ramkanth S, Sankari KU, Alagusundaram M, Gnanapraksah K, Devi DP, et al. Ethosomes-A noninvasive vesicular carrier for transdermal drug delivery. Int J Rev Life Sci 2011; 1(1): 17-24.
[79]
Verma P, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: an overview. J Adv Pharm Technol Res 2010; 1(3): 274-82.
[http://dx.doi.org/10.4103/0110-5558.72415] [PMID: 22247858]
[80]
Razavi H, Janfaza S. Ethosomes: a nanocarrier for transdermal drug delivery. J Paramed Sci Spring 2015; 6(2): 2008-4987.
[81]
Yu Z, Lv H, Han G, Ma K. Ethosomes loaded with cryptotanshinone for acne treatment through topical gel formulation. PLoS One 2016; 11(7)e0159967
[http://dx.doi.org/10.1371/journal.pone.0159967] [PMID: 27441661]
[82]
Mistry A, Ravikumar P. Development and evaluation of azelaic acid based ethosomes for topical delivery for the treatment of acne. Ind J Pharm Educ Res 2016; 50(3): S232-43.
[http://dx.doi.org/10.5530/ijper.50.3.34]
[83]
Kausar H, Muj eb M, Ahad A, Moolakkadath T, Aqil M, Ahmad A, et al. Optimization of ethosomes for topical thymoquinone delivery for the treatment of skin acne. J Drug Deliv Sci Technol 2019; 49: 177-87.
[http://dx.doi.org/10.1016/j.jddst.2018.11.016]
[84]
David SR, Hui MS, Pin CF, Ci FY, Rajabalaya R. Formulation and in vitro evaluation of ethosomes as vesicular carrier for enhanced topical delivery of isotretinoin. Int J Drug Deliv 2013; 5(1): 28.
[85]
Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Critical reviews™ in therapeutic drug carrier systems 1996; 13: 3-4.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.30]
[86]
Nimisha SA, Chaubey R. enhancement of dissolution rate of quercetin using solid dispersion approach: in vitro & in vivo evaluation. Nanosci Nanotechnol Asia 2019; 9: 1.
[http://dx.doi.org/10.2174/2210681209666190919095128]
[87]
Rai S, Pandey V, Rai G. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: the state of the art. Nano Rev Exp 2017; 18(1)1325708
[http://dx.doi.org/10.1080/20022727.2017.1325708]
[88]
Modi CD, Bharadia PD. Transfersomes: new dominants for transdermal drug delivery. Am J Pharm Tech Res 2012; 2(3): 71-91.
[89]
Hasanpouri A, Lotfipour F, Ghanbarzadeh S, Hamishehkar H. Improvement of dermal delivery of tetracycline using vesicular nanostructures. Res Pharm Sci 2018; 13(5): 385-93.
[http://dx.doi.org/10.4103/1735-5362.236831] [PMID: 30271440]
[90]
Rahmi AD, Pangesti DM. Comparison of the characteristics of transfersomes and protransfersomes containing azelaic acid. J Young Pharm 2018; 10(2s): S11-5.
[91]
Qushawy M, Nasr A, Abd-Alhaseeb M, Swidan S. Design, optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. Pharmaceutics 2018; 10(1): 26.
[http://dx.doi.org/10.3390/pharmaceutics10010026] [PMID: 29473897]
[92]
Gupta M, Prajapati RN, Irchhaiya R, Singh N, Prajapati SK. Novel clindamycin loaded transfersomes formulation for effective management of acne. World. Res J Pharm Res 2017; 6(6): 765-73.
[93]
Fadel M, Kassab K, Samy N, Thabet S. Indocyanine green transferosomal hydrogel with enhanced stability and skin permeation for treatment of acne vulgaris: (in-vitro and clinical study). EJPBS 2015; 2: 20-36.
[94]
Rafieian-Kopaei M. Medicinal plants and the human needs. J HerbMed Pharm 2012; 1: 1.
[95]
Mardani S, Nasri H, Hajian S, Ahmadi A, Kazemi R, Rafieian-Kopaei M. Impact of Momordica charantia extract on kidney function and structure in mice. J Nephropathol 2014; 3(1): 35-40.
[PMID: 24644542]
[96]
Rafieian-Kopaei M, Baradaran A. Teucrium polium and kidney. J Renal Inj Prev 2013; 2(1): 3-4.
[PMID: 25340111]
[97]
Kaity S, Maiti S, Ghosh AK, Pal D, Ghosh A, Banerjee S. Microsponges: A novel strategy for drug delivery system. J Adv Pharm Technol Res 2010; 1(3): 283-90.
[http://dx.doi.org/10.4103/0110-5558.72416] [PMID: 22247859]
[98]
Rafieian-Kopaei M, Nasri H, Alizadeh F, Ataei B, Baradaran A. Immunoglobulin A nephropathy and malaria falciparum infection; a rare association. Iran J Public Health 2013; 42(5): 529-33.
[PMID: 23802112]
[99]
Collier K, Matalonis S, Owen AJ. Evaluation of permeability enhancement by microemulsion in a Caco-2 cell system. In: InProc Int Symp Control Release Bioact Mater. 1999; Vol 26: p. 5444.
[100]
Marti-Mestres G, Nielloud F. Emulsions in health care applications—an overview. J Dispers Sci Technol 2002; 23(1-3): 419-39.
[http://dx.doi.org/10.1080/01932690208984214]
[101]
Nimisha FZ, Kaur CD. formulation and performance evaluation of berberis aristata extract loaded ethosomal gel. Asian. J Pharm 2017; 11(3): 176-83.
[102]
Nacht S, Katz M. The microsponge: a novel topical programmable delivery system. Drugs Pharm Sci 1990; 42: 299-325.
[103]
Alebiosu CO, Ogunledun A, Ogunleye DS. A report of clinical trial conducted on Toto ointment and soap products. J Natl Med Assoc 2003; 95(1): 95-105.
[PMID: 12656456]
[104]
Nimisha FZ. Kaur CD. A review on potential of novel vesicular carriers for carrying herbal drugs in the treatment of dermatological disorders. J Atoms Mol 2016; 6(3): 987.
[105]
Lalla JK, Nandedkar SY, Paranjape MH, Talreja NB. Clinical trials of ayurvedic formulations in the treatment of acne vulgaris. J Ethnopharmacol 2001; 78(1): 99-102.
[http://dx.doi.org/10.1016/S0378-8741(01)00323-3] [PMID: 11585696]
[106]
Mahmood T, Akhtar N, Khan BA, Khan HM, Saeed T. Outcomes of 3% green tea emulsion on skin sebum production in male volunteers. Bosn J Basic Med Sci 2010; 10(3): 260-4.
[http://dx.doi.org/10.17305/bjbms.2010.2697] [PMID: 20846135]
[107]
Ravichandran G, Bharadwaj VS, Kolhapure SA. Evaluation of efficacy and safety of Acne-N-Pimple cream in acne vulgaris. Antiseptic 2004; 101(12): 249.
[108]
Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. Med J Aust 1990; 153(8): 455-8.
[http://dx.doi.org/10.5694/j.1326-5377.1990.tb126150.x] [PMID: 2145499]
[109]
Sibinovska N, Komoni V, Netkovska KA, Vranic E, Crcarevska MS, Dodov MG. Novel approaches in treatment of acne vulgaris: patents related to micro/nanoparticulated carrier systems. Macedonian Pharm Bull 2016; 62(2): 3-16.
[110]
Handjani RM, Ribier A, Vanlerberghe G, Zabotto A, Griat J. Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing these compositions US4830857 1989.
[111]
Rasochova L, Michelle KE. Compositions and methods for treating acne vulgaris US16302637 2019.
[112]
Perricone NV. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system US8871254 2014.
[113]
Vivanco RC, Bejarano RA, Torres DP. Inventors; Pharmabrand SA. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis and method for obtaining same and use thereof US8334001 2012.
[114]
Wei X, Dong M, Yujie J. A kind of transdermal drug delivery system of alcohol liposome containing hyaluronic acid and preparation method and application. CN106955277(A) 2017.
[115]
Edelson J, Cotilla T, Zhang B. Dermal delivery CN105147608(B) 2015.
[116]
Perricone NV. Treatment of skin and soft tissue infection with nitric oxide US8871255 2014.
[117]
Tan J, Jiang L, Chang T, Zhou Z. Bullatacin ethosome gel and preparation method thereof CN102552147(A) 2012.
[118]
Tan J, Jiang L, Chang T, Zhou Z. Paclitaxel ethosome gel and preparation method thereof CN102552147A 2012.
[119]
Pisano C, Vesci L. Use of adamatyl methoxydiphenyl propenoic acid for the treatment of acne. US7635719 2009.
[120]
Ayala FA. Topical antiacne preparations containing retinoid (tazarotene or adapalene), antibiotic (clindamycin phosphate) and/or keratolytic (microsponged benzoyl peroxide) US12/375592 2009.
[121]
Susan M, Glen A, Nassiti D. Novel topical formulations KR 20010049428(A) 2008.
[122]
Dorogi P, Vasily D, McCook J. Skin treatment compositions containing copper-pigment complexes. US11/320280 2007.
[123]
Bouwstra JA. Phospholipid-and cholestrol-free aqueous composition for topical application to the skin US5830499 1998.
[124]
Wolf BA, Snyder F. Cosmetic compositions having keratolytic and anti-acne activity US5449519 1995.
[125]
Meybeck A, Michelon P, Montastier C, Redziniak GG. Pharmaceutical composition, in particular dermatological or cosmetic, comprising hydrous lipidic lamellar phases or liposomes containing a retinoid or a structural analogue thereof such as a carotenoid. US5034228 1991.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Published on: 29 July, 2020
Page: [3 - 29]
Pages: 27
DOI: 10.2174/1574891X15999200729192138
Price: $65

Article Metrics

PDF: 27
HTML: 3
EPUB: 1
PRC: 1